Peripheral microRNA signature in genetic frontotemporal dementia—findings from the GENFI initiative. Fenoglio, C., Serpente, M., Arcaro, M., Carandini, T., Sacchi, L., Pintus, M., Borracci, V., Giudici, G., Rigoni, M., Muti, P., Ghezzi, L., Bouzigues, A., Rusell, L. L., Foster, P. H., Ferry-Bolder, E., van Swieten, J. C., Jiskoot, L. C., Seelaar, H., Valle, R. S., Laforce, R., Graff, C., Vandenberghe, R., de Mendonça, A., Tiraboschi, P., Santana, I., Gerhard, A., Levin, J., Pasquier, F., Ducharme, S., Ber, I. L., Finger, E., Tartaglia, M. C., Masellis, M., Rowe, J. B., Synofzik, M., Moreno, F., Borroni, B., Sacconi, A., Rohrer, J. D., Arighi, A., Galimberti, D., Alberici, A., Afonso, S., Alves, P., Anderl-Straub, S., Antonelli, A., Balasa, M., Barandiaran, M., Bargalló, N., Bartha, R., Bender, B., Bernhardt, A. M., Bertoux, M., Bertrand, A., Bessi, V., Black, S., Bocca, G., Bocchetta, M., Borrego-Ecija, S., Brice, A., Bruffaerts, R., Cantoni, V., Caroppo, P., Cash, D., Castelo-Branco, M., Colliot, O., Convery, R., Cope, T., Costa-Coelho, T., Croitoru, I., Camuzat, A., de Boer, L., de Houwer, J., Deramecourt, V., Durães, J., Fede, G. D., Ferrari, C., Florio, G., Frascotti, M., Freedman, M., Funkiewiez, A., Gabilondo, A., Gasparotti, R., Giaccone, G., Giannini, L., Goldsmith, S., Graf, L., Jelic, V., Keren, R., Krüger, J., Kuchcinski, G., Langheinrich, T., Lebouvier, T., Leitão, M. J., Lemos, J., Lima, M., Lladó, A., Lombardi, G., Lombardi, J., Malpetti, M., Maruta, C., Mengel, D., Miltenberger, G., Mitchell, S., Montembault, M., Nacmias, B., Nilsson, M., Öijerstedt, L., Olives, J., Papma, J., Pijnenburg, Y., Poesen, K., Polito, C., Poos, J., Premi, E., Prioni, S., Prix, C., Redaelli, V., Rittman, T., Rademakers, R., Rinaldi, D., Rogaeva, E., Rollin, A., Rosa-Neto, P., Almeida, M. R., Rossi, G., Samra, K., Saracino, D., Sayah, S., Schönecker, S., Shoesmith, C., do Couto, F. S., Stockbauer, A., Tábuas-Pereira, M., Tang-Wai, D., Rydell, M. T., Tainta, M., Thomas, D. L, Vandenbulcke, M., Damme, P. V., van Minkelen, R., Verdelho, A., Viklund, H., Vimercati, R., Vogels, A., Wagemann, O., & Wlasich, E. GeroScience, 4, 2026. Author list abbreviated in original export; additional authors not provided. INTERACTIONS team affiliation requires confirmation.
Peripheral microRNA signature in genetic frontotemporal dementia—findings from the GENFI initiative [link]Paper  doi  abstract   bibtex   

Frontotemporal dementia (FTD) is a neurodegenerative disease characterized by significant clinical and genetic heterogeneity, with approximately 40% of cases linked to hereditary genetic mutations, including MAPT , GRN , and C9ORF72 . Recently, microRNAs (miRNAs) have emerged as key regulators of cellular processes related to neurodegeneration and as potential biomarkers for FTD. However, their relevance in presymptomatic stages remains poorly understood. We conducted a miRNA expression analysis using TaqMan OpenArray® panels on blood samples collected from 171 individuals, including symptomatic mutation carriers (SMC), presymptomatic carriers (PMC), and healthy non-carriers (NC). Dysregulated miRNAs were validated and bioinformatic tools were used to identify potential associated molecular pathways. In C9ORF72 , miR-20b-5p and miR-223-5p were significantly upregulated in SMC (fold regulation over NC: 2.418 p  = 0.0336 and 7.829 p  < 0.0264 respectively) and PMC (5.518, p  < 0.0001 and 3.941, p  < 0.0001 respectively). In GRN mutation carriers, miR-28-3p was altered in both SMC and PMC (fold regulation over NC: 1.484 p  < 0.050 and 3.287, p  < 0.050). In MAPT mutation carriers, miR-28-5p, miR-192-3p, miR-25-3p, and miR-532-3p were altered only in SMC (fold regulation over NC: 1.496 p  < 0.050, 1.911 p  = 0.006, 1.468 p  < 0.05, and 0.728 p  < 0.05). Bioinformatic analysis revealed enrichment of pathways related to neurodegeneration and synapse impairment. These results suggest that miRNA expression levels are deregulated in mutated SMC, in C9ORF72 and GRN PMC. Notably, miR-20b-5p, miR-223-5p, and miR-28-3p were increased in preclinical stages of the disease, supporting their role as early biomarkers for C9ORF72 -FTD and GRN -FTD. Conversely, alterations in MAPT carriers appeared only in symptomatic stages, suggesting a different involvement in disease progression.

@article{Fenoglio2026,
   abstract = {<p> Frontotemporal dementia (FTD) is a neurodegenerative disease characterized by significant clinical and genetic heterogeneity, with approximately 40% of cases linked to hereditary genetic mutations, including <italic>MAPT</italic> , <italic>GRN</italic> , and <italic>C9ORF72</italic> . Recently, microRNAs (miRNAs) have emerged as key regulators of cellular processes related to neurodegeneration and as potential biomarkers for FTD. However, their relevance in presymptomatic stages remains poorly understood. We conducted a miRNA expression analysis using TaqMan OpenArray® panels on blood samples collected from 171 individuals, including symptomatic mutation carriers (SMC), presymptomatic carriers (PMC), and healthy non-carriers (NC). Dysregulated miRNAs were validated and bioinformatic tools were used to identify potential associated molecular pathways. In <italic>C9ORF72</italic> , miR-20b-5p and miR-223-5p were significantly upregulated in SMC (fold regulation over NC: 2.418 <italic>p</italic>  = 0.0336 and 7.829 <italic>p</italic>  &lt; 0.0264 respectively) and PMC (5.518, <italic>p</italic>  &lt; 0.0001 and 3.941, <italic>p</italic>  &lt; 0.0001 respectively). In <italic>GRN</italic> mutation carriers, miR-28-3p was altered in both SMC and PMC (fold regulation over NC: 1.484 <italic>p</italic>  &lt; 0.050 and 3.287, <italic>p</italic>  &lt; 0.050). In <italic>MAPT</italic> mutation carriers, miR-28-5p, miR-192-3p, miR-25-3p, and miR-532-3p were altered only in SMC (fold regulation over NC: 1.496 <italic>p</italic>  &lt; 0.050, 1.911 <italic>p</italic>  = 0.006, 1.468 <italic>p</italic>  &lt; 0.05, and 0.728 <italic>p</italic>  &lt; 0.05). Bioinformatic analysis revealed enrichment of pathways related to neurodegeneration and synapse impairment. These results suggest that miRNA expression levels are deregulated in mutated SMC, in <italic>C9ORF72</italic> and <italic>GRN</italic> PMC. Notably, miR-20b-5p, miR-223-5p, and miR-28-3p were increased in preclinical stages of the disease, supporting their role as early biomarkers for <italic>C9ORF72</italic> -FTD and <italic>GRN</italic> -FTD. Conversely, alterations in <italic>MAPT</italic> carriers appeared only in symptomatic stages, suggesting a different involvement in disease progression. </p>},
   author = {Chiara Fenoglio and Maria Serpente and Marina Arcaro and Tiziana Carandini and Luca Sacchi and Manuela Pintus and Vittoria Borracci and Giulia Giudici and Marta Rigoni and Paola Muti and Laura Ghezzi and Arabella Bouzigues and Lucy L. Rusell and Phoebe H. Foster and Eve Ferry-Bolder and John C. van Swieten and Lize C. Jiskoot and Harro Seelaar and Raquel Sánchez Valle and Robert Laforce and Caroline Graff and Rik Vandenberghe and Alexandre de Mendonça and Pietro Tiraboschi and Isabel Santana and Alexander Gerhard and Johannes Levin and Florence Pasquier and Simon Ducharme and Isabelle Le Ber and Elizabeth Finger and Maria Carmela Tartaglia and Mario Masellis and James B. Rowe and Matthis Synofzik and Fermin Moreno and Barbara Borroni and Andrea Sacconi and Jonathan D. Rohrer and Andrea Arighi and Daniela Galimberti and Antonella Alberici and Sónia Afonso and Patricia Alves and Sarah Anderl-Straub and Anna Antonelli and Mircea Balasa and Myriam Barandiaran and Nuria Bargalló and Robert Bartha and Benjamin Bender and Alexander Maximilian Bernhardt and Maxime Bertoux and Anne Bertrand and Valentina Bessi and Sandra Black and Giorgio Bocca and Martina Bocchetta and Sergi Borrego-Ecija and Alexis Brice and Rose Bruffaerts and Valentina Cantoni and Paola Caroppo and David Cash and Miguel Castelo-Branco and Olivier Colliot and Rhian Convery and Thomas Cope and Tiago Costa-Coelho and Ioana Croitoru and Agnès Camuzat and Liset de Boer and Julie de Houwer and Vincent Deramecourt and João Durães and Giuseppe Di Fede and Camilla Ferrari and Graziana Florio and Marta Frascotti and Morris Freedman and Aurélie Funkiewiez and Alazne Gabilondo and Roberto Gasparotti and Giorgio Giaccone and Lucia Giannini and Sophie Goldsmith and Lisa Graf and Vesna Jelic and Ron Keren and Johanna Krüger and Gregory Kuchcinski and Tobias Langheinrich and Thibaud Lebouvier and Maria João Leitão and João Lemos and Marisa Lima and Albert Lladó and Gemma Lombardi and Jolina Lombardi and Maura Malpetti and Carolina Maruta and David Mengel and Gabriel Miltenberger and Sara Mitchell and Maxime Montembault and Benedetta Nacmias and Mattias Nilsson and Linn Öijerstedt and Jaume Olives and Janne Papma and Yolande Pijnenburg and Koen Poesen and Cristina Polito and Jackie Poos and Enrico Premi and Sara Prioni and Catharina Prix and Veronica Redaelli and Timothy Rittman and Rosa Rademakers and Daisy Rinaldi and Ekaterina Rogaeva and Adeline Rollin and Pedro Rosa-Neto and Maria Rosario Almeida and Giacomina Rossi and Kiran Samra and Dario Saracino and Sabrina Sayah and Sonja Schönecker and Christen Shoesmith and Frederico Simões do Couto and Anna Stockbauer and Miguel Tábuas-Pereira and David Tang-Wai and Melissa Taheri Rydell and Mikel Tainta and David L Thomas and Mathieu Vandenbulcke and Philip Van Damme and Rick van Minkelen and Ana Verdelho and Henrik Viklund and Roberto Vimercati and Annick Vogels and Olivia Wagemann and Elisabeth Wlasich},
   doi = {10.1007/s11357-026-02214-x},
   issn = {2509-2723},
   journal = {GeroScience},
   month = {4},
   note = {Author list abbreviated in original export; additional authors not provided.
INTERACTIONS team affiliation requires confirmation.},
   title = {Peripheral microRNA signature in genetic frontotemporal dementia—findings from the GENFI initiative},
   url = {https://link.springer.com/10.1007/s11357-026-02214-x},
   year = {2026}
}

Downloads: 0